Skip Navigation

Lotus's Korean subsidiary launched the anti-obesity drug Qsymia® in Korea

22 November 2019

Specialty pharmaceutical Lotus Pharmaceutical Co., Ltd (“Lotus” or “the Company”, 1795:TT) today announced that its subsidiary Alvogen Korea Co., Ltd. (Alvogen Korea) has launched anti-obesity drug Qsymia® (phentermine and topiramate extended-release) in Korea. Qsymia® comes in 4 strengths and is developed by VIVUS Inc.

Qsymia® represents a novel treatment option in the anti-obesity therapeutic area and shall reinforce Alvogen Korea’s leadership position in this segment in Korea. Qsymia® is approved by the USFDA in 2012 and is safe for long term use while demonstrating clinically superior weight loss results compared to existing therapies.

Lotus General Manager Petar Vazharov says

Launch of Qsymia® is a very good news for Korean patients and healthcare providers. It also marks as an important milestone in the evolution of our anti-obesity portfolio in Korea. We are very excited about the commercialization of this product and Alvogen Korea will promote Qsymia® jointly with Chong Kun Dang Pharmaceutical Corporation (CKD), the leading Korean pharmaceutical company in both hospital and clinic channels.

Petar Vazharov

Lotus General Manager

According to the latest moving-annual-total data of UBIST, a third-party pharmaceutical marketing research firm, anti-obesity market size in Korea stands at US$111 million in value.